Burnham Institute for Medical Research today announced that scientists have created a peptide that binds to Bcl-2, a protein that protects cancer cells from programmed cell death, and converts it into a cancer cell killer. The research, which was published as the featured article in the October 7 edition of Cancer Cell, may lead to new cancer treatments.
The Bcl-2 protein has long been implicated in protecting cancer cells from apoptosis (programmed cell death), the process that usually keeps cancer cells in check. This peptide (called NuBCP-9) and its enantiomer (mirror-image molecule) work on Bcl-2 like a molecular switch, converting it into a pro-apoptotic protein, and inducing cell death in cancer cells.
"Our results provide insight into Bcl-2 conversion and identify a new direction for Bcl-2-based drug leads and cancer drug development," said Xiao-kun Zhang, Ph.D., who co-authored the paper with Arnold Satterthwait, Ph.D. and others.
The NuBCP-9 peptide was created from Nur77, a potent pro-apoptotic protein. Nur77 often moves from the nucleus to mitochondria, in response to different death signals, where it binds to Bcl-2, changing its shape and function.
Source: Burnham Institute
Explore further: AstraZeneca cancer drug, companion test approved